Claremont BioSolutions LLC

Claremont BioSolutions LLC

Claremont BioSolutions LLC

Overview
Date Founded

2006

Headquarters

1182 Monte Vista Avenue,Suite 11,Upland, CA 91786

Type of Company

Private

Employees (Worldwide)

11 - 50

Industries

Medical Products & Equipment
Market & Policy Research
IT Consulting & Services
Medical Support Services
Hospitals & Patient Services
Holding Companies

Company Description

Claremont BioSolutions LLC operates as a technology company which specializes in disposable devices. Its products include SimplePrep X8 automated lysis & nucleic acid extraction instrument, OmniLyse a rapid cell lysis kits, Homogenization kits, PureLyse, HisExpress, ALFRD, Legato a touchscreen syringe pumps, MicroMesh & transfer tips and filter tips. The company was founded in 2006 by Tracy Doebler, James D. Sterling, Robert Doebler and Ali Nadim and is headquartered in Upland, CA.

Contact Data
Trying to get in touch with decision makers at Claremont BioSolutions LLC? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder & President

Chief Executive Officer

Director of Diagnostics Research & Global Health Initiatives

Board of Directors

President & Founder at RxDx Link

Paths to Claremont BioSolutions LLC
Potential Connections via
Relationship Science
You
Claremont BioSolutions LLC
Investors
Details Hidden

In-Q-Tel invests focuses on investments in start-up companies that have developed commercially-focused technologies that will provide strong, near-term advantages to the intelligence community within 36 months. The firm concentrates on 3 areas within the commercial technology sectors; (1) physical and biological technologies (2) security and (3) software and infrastructure. The firm's investments are designed to accelerate product development and delivery and to help companies add capabilities needed by customers in the intelligence community. In addition, In-Q-Tel leverages their direct investments by attracting a significant amount of private sector funds, often from top-tier venture capital firms, to co-invest in their portfolio companies. Although financial return is not their primary objective, In-Q-Tel's success in creating sustainable companies and viable technologies may produce investment gains when a portfolio company matures and exits into the market. In-Q-Tel is required to reinvest returns into further technologies and programs to benefit the CIA, the intelligence community and the US Government

Details Hidden

Co-Founder & President at Claremont BioSolutions LLC

Details Hidden

Co-Founder at Claremont BioSolutions LLC

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Claremont BioSolutions LLC. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Claremont BioSolutions LLC's profile does not indicate a business or promotional relationship of any kind between RelSci and Claremont BioSolutions LLC.